Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current Deffered RevenueOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)ReceivablesRetained EarningsShareholder's EquityShares OutstandingShort-term InvestmentsTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Day One Biopharmaceuticals (DAWN) Cash & Current Investments (2022 - 2025)

Day One Biopharmaceuticals (DAWN) has disclosed Cash & Current Investments for 4 consecutive years, with $441.1 million as the latest value for Q4 2025.

  • On a quarterly basis, Cash & Current Investments fell 17.04% to $441.1 million in Q4 2025 year-over-year; TTM through Dec 2025 was $441.1 million, a 17.04% decrease, with the full-year FY2025 number at $441.1 million, down 17.04% from a year prior.
  • Cash & Current Investments was $441.1 million for Q4 2025 at Day One Biopharmaceuticals, down from $451.6 million in the prior quarter.
  • In the past five years, Cash & Current Investments ranged from a high of $558.4 million in Q3 2024 to a low of $262.7 million in Q1 2022.
  • A 4-year average of $405.6 million and a median of $397.2 million in 2022 define the central range for Cash & Current Investments.
  • Biggest YoY gain for Cash & Current Investments was 48.77% in 2025; the steepest drop was 19.13% in 2025.
  • Day One Biopharmaceuticals' Cash & Current Investments stood at $342.3 million in 2022, then rose by 7.03% to $366.3 million in 2023, then soared by 45.14% to $531.7 million in 2024, then dropped by 17.04% to $441.1 million in 2025.
  • Per Business Quant, the three most recent readings for DAWN's Cash & Current Investments are $441.1 million (Q4 2025), $451.6 million (Q3 2025), and $453.1 million (Q2 2025).